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Abstract
Background: Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in
Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in
children of Co ´rdoba, Argentina, 2005–2008. Additionally, data from 2007 were compared with the epidemiology of these
infections in other regions of the country.
Methodology/Principal Findings: Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3
Co ´rdoba pediatric hospitals-(CBAH1-H3) in 2007–2008 (compared to previously published data of 2005) and ii) a sampling of
CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors
for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of
Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the
HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005–2008, the annual proportion of CA-
MRSA/CA-S. aureus in Co ´rdoba hospitals increased from 25% to 49%, P,0.01. Total CA-MRSA infections increased 3.6 fold-(5.1
to18.6cases/100,000annual-visits, P,0.0001),associatedwithanimportant increaseofinvasiveCA-MRSA infections-(8.5fold).
In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-
field-gel electrophoresis-(PFGE)-type-‘‘I’’, sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The
second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL
+, accounted for 11.5% of total CA-MRSA infections. Importantly,
the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL
+/ACME
2)
were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and
HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5).
Conclusions/Significance: The dissemination of epidemic MRSA clone, ST5-IV-PVL
+ was the main cause of increasing
staphylococcal community-onset infections in Argentinean children (2003–2008), conversely to other countries. The
predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-
onset cases suggests that it has infiltrated into hospital-settings.
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Introduction
Methicillin resistant Staphylococcus aureus (MRSA) infection has
traditionally been associated with healthcare settings (HA-MRSA)
until its emergence in the community during late 1990’s. This
global phenomenon was caused by strains of community-
associated methicillin-resistant Staphylococcus aureus (CA-MRSA)
that emerged from some major genetic lineages, commonly
designated by their multilocus sequence type (MLST) or by their
pulsed field gel electrophoresis (PFGE) pattern (ST1, ST8-
USA300, ST30, ST59, ST93 and ST80),with a specific geograph-
ical pattern. These strains are frequently non-multiresistant to
antibiotics; most of them harbor the staphylococcal cassette
chromosome mec (SCCmec) type IV(2B) or V(5C2) and the
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soft tissue infections are the most common clinical manifestations
of CA-MRSA, although increasing reports of serious infections in
children with high mortality rates have raised concern during
recent years [4,5]. Vancomycin has been the mainstay of
treatment for this type of infections and the emergence of
resistance is worrying [6,7]. Importantly, CA-MRSA strains have
entered the healthcare settings; hence, in some countries, strains of
both, CA-MRSA and HA-MRSA circulate in hospitals and
communities, causing infections of healthcare or community onset
(HO and CO, respectively) [8–10].
In Latin America, three PVL-positive epidemic CA-MRSA
clones have been described: i) MRSA ST30-IV clone [11], ii)
MRSA ST5-IV clone [12,13] and iii) MRSA ST8-IV clone [14].
The first two were detected in southern areas of South America
and the third one in the North.
Epidemiological surveillance for MRSA in Co ´rdoba, Argentina,
revealed the emergence of ST5-IV-PVL
+ genotype as the most
prevalent (89%) CA-MRSA clone in 2005. This clone had
displaced in the community setting an ‘‘escaped’’ HA-MRSA
clone, which was non-multiresistant to antibiotics, lacked the pvl
genes and was characterized as ST100 associated with a SCCmec
related to IVc [12,15]. Prospective surveillance of community
onset S. aureus infections in children from Argentina during 2007,
detected a prevalence of 62% (281/447 CA-S. aureus) of CA-
MRSA infections; 38% of which were invasive infections [16].
A paucity of data about molecular epidemiology of CA-MRSA
infections from South America is a current problem and therefore,
it is difficult to follow evolving trends [17–19].
Herein, we report the molecular evolution and antimicrobial
resistance profiles of MRSA strains in the community along with
the clinical characteristics of these infections in children of
Co ´rdoba-Argentina between 2003 and 2008.
We also compared the clinical and molecular epidemiology of
CO-MRSA infections in children with risk factors for healthcare-
associated infections (HRFs), (healthcare-associated, community-
onset infections [HACO]), and in patients without HRFs (CA-
MRSA infections), from multiple centers of central, eastern and
northern regions of Argentina during 2007.
Materials and Methods
Ethics statement
This study was reviewed and approved by the institutional
Ethical Review Board of each Hospital: Hospital de Pediatrı ´a Prof.
Dr. Juan P. Garrahan; Hospital General de Nin ˜os Dr. Pedro de
Elizalde; Hospital de Nin ˜os Dr. O. Alassia, Santa Fe; Hospital de
Nin ˜os de San Justo; Hospital Juan Pablo II, Corrientes; Hospital
de Nin ˜os J. Vilela, Santa Fe; Hospital Pedia ´trico Dr. A.L.
Castela ´n, Chaco; Hospital Materno Infantil de Mar del Plata Don
Victorio Tetamanti, Hospital de Nin ˜os de la Santı ´sima Trinidad
de Co ´rdoba, Hospital Infantil Municipal de Co ´rdoba; Hospital
Pedia ´trico del Nin ˜o Jesu ´s de Co ´rdoba. Written informed consent
was obtained from each child’s parents for review of the medical
information and characterizations of the responsible isolates.
However, for the aims of this study, data were processed
anonymously. Additionally, the authors declare that all clinical
investigation has been conducted according to the principles
expressed in the Declaration of Helsinki.
Study design and case definitions
Longitudinal study, Co ´rdoba, 2003–2008. To analyze the
molecular evolution and clinical characteristics of CA-MRSA
infections in children (#18 years of age) in Co ´rdoba, all
consecutive single patient isolates (n: 99) identified as CA-MRSA
according to CDC criteria (see definitions) by a laboratory-based
surveillance program of S. aureus infections during 2007–2008 from
three children’s hospitals (CBAH1, CBAH2 and CBAH3) were
prospectively included.
These molecular data were compared with those obtained in
2005 [12]. In that year, all S. aureus infections were identified by
the Clinical Microbiology Laboratory of each hospital (CBAH1,
CBAH2 and CBAH3) and the medical records were reviewed for
epidemiologic classification (see definitions).
Additionally, 22 CA-MRSA isolates prospectively collected in
CBAH1 between 2003 and 2006 following the CDC criteria (see
definition) were analysed as well, along with those detected for this
study (2007–2008).
Transversal study, Argentina, 2007. To examine the
clinical and molecular epidemiology of CA-MRSA and HACO-
MRSA infections among children from central, northern and
eastern regions of Argentina in 2007, random samples
representative of each hospital participating in the prospective
surveillance of community onset S. aureus infections in children
from Argentina (CSACHARG) were analyzed. The clinical
features, frequency and outcome of CA-MRSA infections
identified in that study have already been published [16].
Briefly, a total of 840 S. aureus infections were diagnosed during
2007, 582 of them were of community onset; among them, 135
children with HRFs were excluded from that study (75 infected
with HACO-MRSA and 60 with HACO-MSSA). Of the
remaining 447 isolates, 281 (62%) were CA-MRSA and 160
CA-MSSA. The following sample was selected for this study: CA-
MRSA isolates: 213 of 281 (Buenos Aires city: 101, Buenos Aires
province: 11, Corrientes: 22, Chaco: 19 and Santa Fe: 60).
HACO-MRSA isolates: 51 of 75 (Buenos Aires city: 25, Buenos
Aires province: 5, Corrientes: 5, Chaco: 5 and Santa Fe: 11).
For each caseofS. aureusisolated fromcommunity onset infections
from both collections (CBAH1-H3 and CSACHARG), the relevant
medical information was examined, including diagnosis, site and
clinicaldetailsofinfection,treatmentinformation,demographicdata
(age, gender), underlying illnesses (chronic conditions) [8,20] and the
presence of the following risk factors for healthcare-associated
infections: existence of an invasive device (e.g., vascular catheter, G-
tube); any history of MRSA infection or colonization, surgery,
hospitalization, dialysis, or residence in a long-term care facility
within the 12 months prior to the culture [21–23].
Definitions
Community-associated methicillin resistant S. aureus (CA-
MRSA) infections were defined as cases from patients without
HRFs during the previous year, who acquired the infection outside
hospital settings or within 48 h of admission, according to the
CDC criteria [22].
Healthcare-associated infections (HA-MRSA) were defined using
previously published definitions [21,22], which include: i) the
classicalnosocomialorhospital-onsetinfection(HO-MRSA),defined
as a those occurring .48 h after hospital admission, not present on
admission (no cases of this type were analyzed in this study) and ii)
Healthcare-associated community-onset (HACO-MRSA) infections:
those occurring in patients with HRFs, having a positive culture
within #48 h after hospital admission. Hence, Community-onset
methicillin resistant S. aureus (CO-MRSA) infections include both the
CA-MRSA and HACO-MRSA infections.
Invasive infections were defined by one or more of the following
conditions: bacteremia, endocarditis, pneumonia, pleural abscess,
lymphadenitis, septic arthritis, osteomyelitis, necrotizing fasciitis,
pyomyositis or another illness in which S. aureus was isolated from
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basis of the systemic inflammatory response syndrome criteria
[24]. Skin diseases (skin and soft tissue, SSTI) were defined as a
primary skin infection such as an abscess, cellulitis, folliculitis or a
skin infection spreading to contiguous tissues.
Surgical site infections (SSI) were not considered as skin
diseases.
Bacterial isolates and antimicrobial susceptibility
Staphylococcus aureus were identified by standard microbiologic
procedures. Antimicrobial susceptibility testing was performed by
disk diffusion method [25]. A disc approximation test (D test) was
used to detect inducible clindamycin resistance [25]. Screening for
reduced susceptibility to vancomycin (VISA and h-VISA) was
performed on all CO-MRSA isolates. Vancomycin and teicopla-
nin minimum inhibitory concentrations (MICs) were determined
by agar dilution method [25]. In addition, all MRSA isolates with
a MIC of 1 or 2 mg/ml were further screened by 2 additional agar
methods: MHA5T-Mueller-Hinton-agar and BHI4V-brain-heart-
infusion-agar (5 mg/ml teicoplanin and 4 mg/ml vancomycin,
respectively) [6,26,27]. MRSA isolates that were positive in at least
one screening test were additionally tested by both, the Etest
Macromethod (MET) and Etest glycopeptide-resistance detection
strip-GRD E-test strips, (bioMe ´rieux-CD) [6,28]. The strains h-
VISA-Mu3 and VISA-Mu50 and the vancomycin-susceptible S.
aureus strain ATCC 29213 were tested for all methods in parallel as
positive and negative controls, respectively.
Molecular typing and detection of genes associated with
virulence
In all CO-MRSA isolates, the PFGE of SmaI digests of
chromosomal DNA were performed and interpreted as previously
described [12]. SmaI restriction patterns (PFGE) were digitized,
presented schematically and analyzed to calculate the Dice
coefficient of correlation and to generate a dendrogram by the
unweighted-pair group method using average linkage clusterings.
Isolates differing by up to six fragments were considered to be
subtypes of a given clonal type, and the similarity cut-off was 80%.
All CO-MRSA isolates were screened by PCR for accessory
gene regulator (agr) type and for 22 specific staphylococcal
virulence genes, as described elsewhere [12 and reference therein],
comprising sequences specific for enterotoxins: sea, seb, sec, sed, see,
seg, seh, sei, sej, sen, seo, sem and sek; toxic shock syndrome toxin
1(TSST-1): tst; exfoliative toxins: eta and etb; PVL genes: lukS-PV-
lukF-PV; leukocidin: lukE-lukD and the class F leukocidin: lukM;
bacteriocine (bsa), adhesins: for collagen (cna) and for bone
sialoprotein-binding protein (bbp). Detection of arcA gene, an
indicator of the arginine catabolic mobile element (ACME), was
analyzed with primers designed in this study, based on the
previously determined sequence of strain USA300_FPR3757
(accession NC_007793). The primer sequences are as follows:
arcA-F 59-TCT ATT ACT GAG CCA GAA GTA CG-39and
arcA-R 59-CAC GTA ACT TGC TAG AAC GAG TA-39, whose
product has 733 bp expected size. USA300-0114 was used as
reference strain for the USA300 clone.
Representative isolates of the most prevalent subtype (defined
by PFGE) from all CO-MRSA strains were also characterized by
multilocus sequence typing and spa typing [29,30].
SCCmec typing
The SCCmec types (I–VI) were evaluated for all CO-MRSA
isolates by multiplex PCR [31] and by allotyping by conventional
PCR [32]. SCCmec type IV was further sub-typed using published
primers [33]. Furthermore, the assignment to the class B mec
complex was confirmed by PCR with primers specific for yIS1272
and mecR1 [34]and in order to differentiate the types of SCCmec
IV and VI, the ccrAB typing was completed by PCR detection with
primers specific for ccrAB allotype 4 [34].
To investigate the presence of SCCmec IV(2B&5) [35], all
isolates belonging to pulsotype C/ST100 associated with a new
variant of SCCmec IV (IVNv), which was positive by PCR for J1
specific region of the SCCmec subtype IVc and ccrAB2 but negative
for B mec complex [15], were further characterized for the mecA
downstream vicinity with primers designed based on the sequence
previously determined of strain ZH47-(ST100), accession
AM292304, (File S1).
The primer sequences are as follows (location relative to the
ZH47 sequence given in parentheses): i) Tn4001-1-F, 59-GCC
AAT CGC TTA ATT GGA GCC G-39 (18.146 to 18.167) and
Tn4001-1-R, 59-ACT TCA TCT TCC CAA GGC TCT GT-39
(18.854 to 18.832); amplifying the region IS1256L-aac(29)—aph(60)
within the Tn4001. ii) Tn4001-2-F, 59-TGG CCA TCA CGT
GTT CTG GG-39 (21.164 to 21.183) and Tn4001-2-R, 59-TCG
GAT GTC TGT CCG AGG ACT-39 (22.131 to 22.111);
amplifying the region between the IS256R (Tn4001) and IS1272
from mec complex B and iii) Tn4001-3-F, 59-ACC AAA CCC
GAC AAC TAC AAC TAT-39 (15.976 to 15.999) and Tn4001-3-
R, 59-GTG TCG TAA AGC TGC GCT CA-39 (17.273 to
17.2554); amplifying the region between the mecA locus and
IS256L (Tn4001). The amplicons with the expected size were end
sequenced and compared to the SCCmec IV(2B&5) sequence, in
the ZH47 strain-(ST100) [35]. All primers used for SCCmec IVNv
characterization are shown in detail in (File S1).
Statistical analysis
Bacteriologic and patient data were compiled in an electronic
database using Access (Microsoft). Data were analyzed with Epi
Info version 6.0.4 software (Centers for Disease Control and
Prevention, Atlanta, GA). Comparisons between groups were
performed with chi-square test or Fisher’s exact test, as
appropriate. P,0.05 was considered statistically significant.
Results
Temporal trends in CA-MRSA infections
During 2007–2008, CA-MRSA accounted for 45% (99 CA-
MRSA/221 CA-S. aureus) of community-associated S. aureus
infections in pediatric patients cared for in three children’s
hospitals of Co ´rdoba, [38% (36/94) in 2007 and 49% (63/127) in
2008]. Hence, these data indicate a significant increase of the
annual prevalence of CA-MRSA infections since 2005 [33% (7/
21) for a three-month period [12] and 25% (18/71) annually,
P,0.01 for trend]. Additionally, the overall rate of CA-MRSA
infections increased significantly (3.6 fold) accounting for 5.1 to
18.6 cases/100,000 annual visits in 2005 and 2008, respectively,
P,0.0001 (Figure 1). In contrast, the incidence of CA-MSSA
infections only increased 1.1 fold, from 16.2 cases in 2005 to 19.1
cases/100,000 annual visits in 2008. The number of children with
invasive CA-MRSA infections in three Co ´rdoba children’s
hospitals increased significantly from 1.3 in 2005 to 11.1 cases/
10,000 admissions in 2008, P,0.001.
Similar trends were observed yearly in one of these hospitals
(CBAH1) upon analysis of the incidence (CA-MSSA, total CA-
MRSA and invasive CA-MRSA infections, Figure 1) from 2003 to
2008.
The characteristics, origin and incidence of CA-MRSA during
2007 in all hospitals are shown in Table 1. Importantly, the rates
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central, eastern and northern regions of Argentina, reaching an
overall rate of 14.2 cases/100,000 annual visits (range 6.9–27) in
2007 (Table 1).
Community onset MRSA infections: Demographic and
clinical data
The distribution of CA-MRSA infections (Co ´rdoba, 2007–2008
and CSACHARG, 2007) and HACO-MRSA infections (CSA-
CHARG, 2007) regarding patient’s clinical features, age and sex
are shown in Table 2. Although children from Co ´rdoba with CA-
MRSA infections were significantly older than children from
CSACHARG, both groups were comparable in sex, type and
severity of the infections (Table 2).
Similar types of invasive CA-MRSA infections (n: 7) were
detected in CBAH1 during 2003–2006: osteomyelitis (n: 2),
arthritis (n: 1), pneumonia (n: 1), bacteremia (n: 1), lymphadenitis
(n: 1) and necrotizing fasciitis (n: 1).
Among selected children with HACO-MRSA infections (n: 51),
multiple risk factors ($2) were found in 35 (68%). The most
common HRFs were: presence of indwelling catheters or
percutaneous medical devices (85%) and hospitalization within
the previous year (73%). In addition, 70% of the patients had
chronic diseases, including immunodeficiencies (human immuno-
deficiency virus-HIV/acquired immunodeficiency syndrome-
AIDS and malignancies), cardiovascular diseases, chronic pulmo-
nary diseases, chronic renal insufficiency, diabetes, or chronic skin
illnesses. These children were more likely to develop invasive
infections (65% vs 33%) and presentation with sepsis (27% vs 13%)
than children with CA-MRSA infections. Invasive HACO-MRSA
cases included mainly lungs and bloodstream infections. In
addition, they had significantly lower frequency of SSTI infections
(12% vs 67%).
Moreover, 23% of HACO-MRSA isolates were obtained from
surgical site infections (Table 2).
The isolates from invasive CA-MRSA infections from CBAH1-
H3 and CSACHARG groups (total n: 104) were obtained from
blood (74%), other normally sterile body sites including joints
(8%), bone (8%), pleural fluid (6%), other body fluids (2%) and
other sites (1% each).
Antimicrobial susceptibility profile of community-onset
MRSA strains
From all CA-MRSA isolates (n: 312) recovered from the
CBAH1-3 and CSACHARG groups during 2007–2008, 20%
were resistant to at least one non-b-lactam antibiotic. Resistance to
erythromycin (ERY-15%), clindamycin (CLI-14%, 93% of
inducible resistance); gentamicin (GEN-8%), rifampin (RIF-2%)
and chloramphenicol (CHL-1%) were detected. The HACO-
MRSA isolates showed significantly (P.0.001) higher rates of
resistance to ERY (45%), CLIN (42%, 23% inducible); GEN
(43%) and RIF (14%) than the CA-MRSA isolates. In addition,
resistance to ciprofloxacin (22%) and to trimethoprim-sulfameth-
oxazole (6%) were only detected among HACO-MRSA isolates.
All isolates were susceptible to vancomycin by agar dilution
method (MIC90, 1 mg/mL; MIC range, 0.25–2 mg/mL) and
teicoplanin (MIC90, 2 mg/mL; MIC range, 0.25–4 mg/mL). From
the total 363 CO-MRSA isolates evaluated, only 3 MRSA from
children with HRFs (HACO-MRSA infections), were found to be
h-VISA.
Figure 1. Evolution of community-associated Staphylococcus aureus infections from children in Cordoba-Argentina, 2003–2008.
Evolution of the rates of all community-associated Staphylococcus aureus infections: i) methicillin-resistant S. aureus (CA-MRSA) infections [total
(squares) and invasive-INVI (circles)], and ii) total methicillin-susceptible S. aureus (CA-MSSA) infections (triangles) in Co ´rdoba children’s hospitals, [H1
(CBAH1): 2003–2008: filled figures, and in H1, H2 and H3 (CBAH1-3): 2005 vs 2007–2008: empty figures] iii) methicillin-resistant community-associated
Staphylococcus aureus infections caused by the ST5-IV-PVL
+clone [total (gray squares) and invasive (INVI) (gray circles)] in H1 (CBAH1): 2003–2008.
doi:10.1371/journal.pone.0030487.g001
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strains: CA-MRSA and HACO-MRSA
The molecular characteristics [sequence type (ST, as defined by
MLST), clonal complex (CC), agr allotype, PFGE, SCCmec and
spaA types, presence of pvl genes and virulence genes profile, along
with the drug resistance pattern of the most predominant
pulsotypes are shown in Table 3. The distribution of the most
predominant genotypes of CO-MRSA isolates involved in invasive
and non invasive infections according to the epidemiologic case
classification (CA-MRSA and HACO-MRSA) are shown in
Table 4. The molecular characterization of the three h-VISA
strains demonstrated that they belonged to three different MRSA
clones (Table 3).
CA-MRSA clone ST5-IV. PFGE performed on 363 isolates
(312 CA-MRSA and 51 HACO-MRSA) revealed a predominant
major pulsotype, (‘‘I’’; 79%, 285/363 isolates) with a more
frequent subtype, I-1 (71%, 202/285). All isolates belonging to the
pulsotype ‘‘I’’ were characterized as agr 2, ST5, except two isolates
belonging to a new single locus variant (SLV) of ST5: ST1524,
CC5 (Clonal Complex), spa-t311 (91% of isolates) and related
(t002, t045; t067; t1094). Most of them were associated with
SCCmec type IV(2B), 96% with subtype IVa:, 2% with subtype
IVc and one isolate was nominated as SCCmec type IV non
typable (IVNT), since it was positive by PCR for ccrB2 and mec
gene complex class B, but negative for J1 regions: a, b, c, d, g and
h (Table 3). Two isolates (I18 subtype) were positive only for ccrC
locus and negative for J1 region of SCCmec V and for other
SCCmec regions analyzed [31] so they were tentatively designated
as SCCmec related to V (Vr) (Table 3).
The pvl genes were not detected in 9% of the ‘‘I’’ pulsotype
isolates (26/285) (Table 3 and Figure 2A). There was considerable
diversity among the PFGE patterns of these isolates, demonstrat-
ing an ongoing evolution: 13 subtypes from 26 PVL
2 isolates vs 15
subtypes from 259 PVL
+ isolates. Unlike PVL
+ isolates, within the
PVL
2 group, spa-t002 (85%) was much more prevalent than spa-
t311 (4%); and did not have the sea gene.
Additionally, all isolates belonging to pulsotype ‘‘I’’ recovered in
CBAH1 during 2003–2006 (n: 20) were characterized as ST5, spa-
t311, associated with SCCmecIVa as well as they harbour pvl and
sea genes.
This clone represented 79% of all community-onset MRSA
isolates (285/363) in both groups of infections, CA-MRSA (82%,
256/312) and HACO-MRSA (57%, 29/51) (Figure 2 and
Table 4). Moreover, this pulsotype predominated among CA-
MRSA isolated in CBAH1 during 2003–2006 (91%, 20/22).
Longitudinal analysis of CA-MRSA infections at this hospital
demonstrated that the significant increase of the incidence of both
total CA-MRSA infections and invasive CA-MRSA infections
were due to the dissemination of this single pulsotype ‘‘I’’ (ST5-
SCCmecIV-PVL
+) increasing from 1 to 25 cases of CA-MRSA
infections between 2003 and 2008 (Figure 1).
On the other hand, both groups, PVL
+ and PVL
2 variants,
produced invasive infections in similar proportions (35%, 90
invasive infections/259 PVL
+ MRSA infections vs 35%, 9 invasive
infections of 26 pulsotype ‘‘I’’-PVL
2 MRSA infections; P=0.96).
Moreover, both groups were comparable regarding sepsis
presentation (13%, 33/259 PVL
+ vs 12%, 3/26 PVL
2; P=0.8).
Southwest Pacific (SWP) clone. The second prevalent clone
among total community-onset MRSA isolates (11%, 39/363) was
the N pulsotype or Southwest Pacific (SWP) clone. It was
characterized as agr 3, ST30 (4 isolates as ST196/SLV)
belonging to CC30, spa-t019 and related t021, t6653 (new spa
type described for the first time in this study) and spa-t975. Most
isolates harbored SCCmecIVc, (97%) and all of them carried the pvl
genes. This genetic background accounted for 11.5% (36/312) and
6% (3/51) of CA-MRSA and HACO-MRSA isolates respectively
(Table 4). The molecular characteristics of this clone and its
distribution in different regions of Argentina during 2007 are
shown in Table 4 and Figure 2. In addition, this clone was
significantly more frequent in Buenos Aires city and surrounding
areas (21%) than in other regions of Argentina (average 8%,
range=729, P=0.009, Figure 2B).
Table 1. Characteristics, incidence of CA-MRSA infections and location of children’s hospitals of northern, eastern and central of
Argentina, 2007.
Children’s Hospitals Province Number of beds Annual admission Annual visits
b Number of CA-MRSA
a 2007 Incidence
c
H1 Co ´rdoba 230 10,375 119,365 16 13.4
H2 Co ´rdoba 75 3,083 123,000 10 8.1
H3 Co ´rdoba 70 1,775 107,000 10 9.3
H4 Santa Fe 96 8,000 220,000 29 13.2
H5 Buenos Aires 274 6,756 202,000 14 6.9
H6 Buenos Aires city
surrounding areas
142 7,539 264,938 33 12.5
H7 Santa Fe 178 13,169 175,683 48 27.3
H8 Autonomous city
of Buenos Aires
485 18,427 296,452 53 17.9
H9 Autonomous city
of Buenos Aires
228 8,917 252,083 42 16.7
H10 Corrientes 152 8,707 181,671 28 15.4
H11 Chaco 78 3,273 214,091 24 11.2
aNumber of all CA-MRSA isolates detected in the three Cordoba children’s hospitals during 2007 and those recovered in each hospital from the surveillance study for
community onset S. aureus infections in children from Argentina-(CSACHARG) [16].
bannual visits: include outpatient facility and emergency service.
cIncidence: Number of cases/100,000 annual visits.
doi:10.1371/journal.pone.0030487.t001
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MRSA clone, non-multiresistant to antibiotics, named pulsotype C
or D by Sola et al and Corso et al, respectively, clonally related to
the Pediatric clone by PFGE analysis [36,37] was also detected. It
was characterized as agr 2, ST100, belonging to CC5, spa-t002,
associated with a SCCmecIV new variant (SCCmec IVNv), and
PVL
2 [12,15].
In this study, Tn4001 was detected, integrated into the class B
mec complex upstream of the mecA gene (class B2 mec gene complex)
by means of PCR typing of different regions of SCCmecIV in
representative isolates of the most frequent subtypes (File S1).
Hence, this new variant of SCCmecIV, in addition to class B2 mec
gene complex, also carries type 2 ccr gene complex and a J1 region
with homology to SCCmecIVc, but unlike the SCCmecIV(2B&5), it
lacks of an SCC with ccrC and contains dcs gene.
This clone was significantly more frequent among HACO-
MRSA infections (10%, 5/51) than among total CA-MRSA
infections (2%, 5/312), P=0.009, (Table 4).
South American USA300 clone. Four CA-MRSA isolates
(one detected in Buenos Aires in 2007 and three in Co ´rdoba
during 2007–2008) were clonally related by PFGE to the USA300
MRSA epidemic strain. They belonged to ST8, CC8, spa-t008 and
to agr 1. Three of these isolates were associated with SCCmecIVc
and one, with subtype IVa. All of them carried the pvl, bsaA and
seK genes. In contrast, all lacked of the arcA gene, which is an
indicator of the presence of the ACME. The isolate associated with
SCCmecIVa also carried sed and sej genes (Figure 2A and Table 3).
Other minor clones. Among CA-MRSA isolates, other
minor pulsotypes were also detected accounting cumulatively for
only 4% of isolates (n: 10, less than 2% each), (Table 3). Among
these, two isolates were characterized as ST188/CC1 and
associated with SCCmecVr constituting the first time that this
genotype is reported in America [19].
The MRSA strains traditionally associated with nosocomial
infections in Argentina [12,15,36,37] only accounted for 37% of
the total HACO-MRSA infections (Cordobes/Chilean-pulsotype
Table 2. Demographic and clinical characteristics of children with Community-onset methicillin resistant S. aureus infections in
central, northern and eastern regions of Argentina.
Characteristics
CA-MRSA
CBAH1-H3
a
CA-MRSA
CSACHARG
b P
c
CA-MRSA Total CBAH1-H3
a
and CSACHARG
b
HACO-MRSA
CSACHARG
b P
c
Period 2007–2008 2007 2007
n(%), [n] n: 99(%), [n]: 5 n: 213(%), [n]: 25 n: 312(%), [n]: 30 n: 51(%), [n]: 4
Age, median of years (range) 6.1 (0.24–18) 3.4 (0.08–16) 4.1 (0.08–18) 3.2 (0.08–18)
Sex (males)
d 61(61) 128(60) 0.93 189(60) 30(59) 0.88
Type and Severity of Infection
d
Skin and soft-tissue (SSTI)
Abscess and cellulites
e 72(73) 136(64) 0.11 209(67) 6(12) ,0.001
Necrotizing Fasciitis 1(1) - 1(0.5) -
Surgical Site (SSI) - - - 12(23)
Musculoskeletal 16(16), [2] 32(15), [11] 0.26 48(15), [13] 6(12), [2] 0.5
Osteomyelitis 11(11), [2] 17(8), [10] 28(9), [12] 5(10), [1]
Septic arthritis 5(5) 13(6) 18(5.5) -
Pyomyositis - 2(1), [1] 2(0.5), [1] 1(2), [1]
Respiratory 5(5), [1] 23(11), [7] 0.09 28(9), [8] 9(17), [1] 0.06
Pneumonia 5(5), [1] 11(5), [2] 16(5), [3] 6(12), [1]
Pleural abscess - 12(6), [5] 12(4), [5] 3(6)
Bacteremia 2(2) 15(7) 0.06 17(5.5) 12(23) ,0.001
Endocarditis 1(1), [1] 1(0.5), [5] 2(0.5), [6] [1]
Pericarditis - 1(0.5) 1(0.5) -
Deep abscess
f [1] 4 (1.5), [1] 4(1), [2] 2(4)
Lymphadenitis 2(2) 1(0.5) 3(1) 1(2)
Meningitis - [1] [1] 3(6)
Invasive Infection
d 27(27) 77(36) 0.12 104(33) 33(65) ,0.001
Sepsis
d 11(11) 29(13) 0.38 40(13) 14(27) 0.008
CA-MRSA: Community-associated methicillin resistant Staphylococcus aureus, HACO-MRSA: Healthcare-associated community-onset methicillin resistant Staphylococcus
aureus infections.
aCBAH1-H3: Prospective surveillance of CO-S. aureus infections in children from three children’s hospitals of Co ´rdoba (CBAH1, CBAH2 and CBAH3), 2007 and 2008.
bCSACHARG: Prospective surveillance of CO-S. aureus infections in children from Argentina, 2007 [16].
cP values are based on chi-square test or Fisher’s exact test, as appropriate, for CA-MRSA,CBAH1-H3 vs. CA-MRSA, CSACHARG and total CA-MRSA vs. HACO-MRSA
comparisons by each of categorical variables (males and infection type); p,0.05 was considered statistically significant.
dValues are number of patients and the percentages are indicated in parentheses. [n]: number of patients with this secondary infection focus (CA-MRSA: 342 infections
in 312 patients).
eAbscess and cellulites: include 9 cases of impetigo(1 from CBAH1-H3 and 8 cases from CSACHARG).
fDeep abscess included: breast (2 cases), psoas (4 cases), liver and renal (1 case each one) abscesses.
doi:10.1371/journal.pone.0030487.t002
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10% and Brazilian-pulsotype B-ST239-IIIA-t037: 6%, Figure 2A
and Table 4).
Discussion
Laboratory-based surveillance of community-associated S. aureus
infections in three children’s hospitals in Co ´rdoba-Argentina
during 2007–2008 revealed a significant increase of the annual
prevalence of CA-MRSA infections since 2005 (49%, 2008 vs
25%, 2005). Moreover, the incidence of CA-MRSA infections
among children tripled over that time frame, associated with an
8.5-fold increase in invasive CA-MRSA infections, despite the
almost stable overall rate of CA-MSSA infections (1.1 fold
increase). A similar pattern with a steady annual increase of CA-
MRSA infections and a slight increase of CA-MSSA infections was
detected in one (H1) of these hospitals between 2003 and 2008.
Hence, we demonstrated that in Co ´rdoba, Argentina, as reported
in some regions of United States, particularly in patients with skin
and soft-tissue infections, CA-MRSA strains are adding to the
burden of CO-S. aureus infections, instead of replacing other S.
aureus strains [8,38].
Unlike in North America, few studies have documented the
epidemiology of MRSA infections in the community among Latin-
American children [1,12,39]. This study provides the first
comprehensive description carried out in Argentina about the
evolution of CA-MRSA infections over time (2003–2008) in
children from Co ´rdoba.
The types of CA-MRSA infections detected in this study are
similar to those described worldwide. Nevertheless, it is important
to remark the high proportion of children with invasive CA-
MRSA infections in Argentina (33%) compared to previous
reports from other countries (1–12%) [20,40]. Regarding HACO-
MRSA infections, most children had some type of chronic disease
and multiple HRFs, were more susceptible to surgical site and
invasive infections as well as sepsis, and had significantly lower
frequency of SSTIs compared to children with CA-MRSA
infections, in agreement with other studies [4,21,41].
Although variable rates of CA-MRSA infection among children
from different regions of Argentina were detected in 2007, one of
the most striking finding of our study is that one major CA-MRSA
clone (I-ST5-SSCmecIV-PVL
+) is currently predominanting in
both groups: community-associated cases (82%) and healthcare-
associated, community-onset cases (57%) in hospitals of northern,
eastern and central regions of our country, contrasting with other
countries [4].
Therefore, the wide dissemination of this clone over all these
regions of Argentina, along with the continued steep rise of its
incidence over time in Co ´rdoba, confirm its epidemic nature.
Importantly, these results suggest that many children, despite
documented contacts with healthcare delivery, are frequently
infected with a CA-MRSA clone. This finding, though indirectly,
suggests that this clone has entered into the healthcare settings and
thus, represents a potentially serious public health challenge for next
years, as described elsewhere for other CA-MRSA clones [8–10].
The molecular characteristics shared by the isolates belonging
to this major clone corresponded largely to those reported in our
previous paper [12], namely, agr2, ST5, spa-t311 and related ones,
SCCmecIV(2B) (96% IVa). In addition, most of these isolates
carried pvl and sea genes (91%). Although most of CA-MRSA
infections (invasive and non invasive) caused by the ‘‘I’’ clone have
been produced by PVL
+ isolates, both groups, PVL
+ and PVL
2,
were comparable regarding the proportions of invasive infections
and presentation with sepsis. Hence, these results lead to
hypothesize that the presence of pvl and sea genes associated with
spa-t311 in this lineage would be more related to a possible
increase in transmissibility and fitness of this CA-MRSA clone,
rather than to its virulence. Further studies are needed to confirm
this hypothesis.
Recently, Nu ¨bel et al [42], by using single-nucleotide polymor-
phism analysis, demonstrated that much of the population
structure of ST5 is local, with multiple independent introductions
of SCCmec, producing a regional-specific evolution of particular
sublineages. In agreement with that hypothesis, in previous studies
we demonstrated the presence of ST5-PVL
+ lineages among
MSSA strains in our country [12,43]. In this study, 9% of the
isolates belonging to I pulsotype were PVL
2. Additionally, among
the isolates characterized as I9 subtype-spa-t311-SCCmecIVa, we
also found one PVL
2 variant and another harboring SCCmecIVc
Table 4. Genotypes of methicillin resistant S. aureus (MRSA) isolates recovered from children with Community-onset infections
(invasive and non-invasive) in central, northen and eastern regions of Argentina, by epidemiologic case classification.
Community onset (CO), N6 (%) of cases & N6 (%) of INVI isolates in indicated epidemiologic class
Total CO Community–Associated (CA)
Healthcare-associated
CO (HACO)
Genotypes
c CBAH1-H3
a 2008 CBAH1-H3
a 2007 CSACHARG
b 2007 Total CA CSACHARG
b 2007
I-ST5-IV 285 (79); 99 (72) 57 (90); 14 (82) 29 (80); 7 (70) 170 (80);61 (79) 256 (82);82 (79) 29 (57);17 (51)
N-ST30-IV 39 (11), 11 (8) 3 (5), 2 (12) 3 (8); 1 (10) 30 (14); 7 (9) 36 (11.5); 10(10) 3 (6); 1 (3)
USA300-ST8-IV 4 (1); 3 (2) 2 (3); 1 (6) 1 (3);1 (10) 1 (0.5), 1 (1) 4 (1), 3 (3) —
C-ST100-IVNv 10 (3); 6 (4) — 1 (3); — 4 (2); 2 (2.5) 5 (2); 2 (2) 5 (10); 4 (12)
A-ST5-I 12 (3); 10 (7) — 1 (3); 1 (10) — 1 (0.5); 1 (1) 11 (21); 9 (27)
B-ST239-IIIA 3 (1); 2 (1.5) — — — — 3 (6); 2 (6)
OTHERS 10 (2) 1 (2) 1 (3) 8 (3.5) 10 (3) —
Total n: 363 & INVI: 137 n: 63 & INVI: 17 n: 36 & INVI: 10 n: 213 & INVI: 77 n: 312 & INVI: 104 n: 51 & INVI: 33
INVI: Invasive infections.
aCBAH1-H3: Prospective surveillance of CO-S. aureus infections in children from three children’s hospitals of Co ´rdoba (CBAH1, CBAH2 and CBAH3) 2007 and 2008.
bCSACHARG and: Prospective surveillance of CO-S. aureus infections in children from Argentina, 2007 [16].
cGenotypes are denoted as: type (by PFGE)-Sequence Type (ST by MLST)-SCCmec type.
doi:10.1371/journal.pone.0030487.t004
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30487Figure 2. Molecular characteristics and proportion from different regions of Argentina of dominant community methicillin-
resistant-Staphylococcus aureus clones. A. PFGE pattern analysis for representative isolates belonging to the most prevalent subtypes of
community-onset-MRSA clones (CA-MRSA and HA-MRSA) detected in central, eastern and northern regions of Argentina during 2007–2008. The
schematic presentation of SmaI restriction patterns (middle) and dendrogram (left) by the unweighted-pair group method using average linkage
clusterings are shown. Genotypes are denoted as subtype (by PFGE)-ST (by MLST)-SCCmec type-spa type (right). CA-MRSA clones appear in gray. The
presence (+) or absence (2)o fpvl genes (by PCR) is also indicated for each subtype; strains with and other without pvl genes belonging to the same
PFGE subtype (I9) are indicated as +/2. The PFGE pattern of USA300-0114 (ST8-IVa-t008-ACME+) is shown for comparison purposes. The first (A1-ST5-
I-t149-Cordobes/Chilean), second (B1-ST239-IIIA-t037-Brazilian) and third (C1-ST100-IVNv-t002-Pediatric) more frequent HA-MRSA clones in our
country, detected among community-onset MRSA infections, are also shown (dotted gray). B: Proportion of CA-MRSA clones among representative
isolates from different regions of Argentina in 2007.
doi:10.1371/journal.pone.0030487.g002
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PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e30487(Figure 2A). Together, these results support the hypothesis about
multiple independent acquisitions of different SCCmec types (IVa
or IVc or Vr) and virulence genes (pvl and sea) by a common ST5
MSSA ancestor.
On the other hand, some studies have described the ST5-
SCCmecIV-PVL
+ genotype among CA-MRSA isolates in United
States and some countries of Europe and Africa. However in all of
them, the isolates had different profiles of virulence genes and/or
resistance to antibiotics and so far, its role as dominant genetic
background of CA-MRSA over time has not been duplicated
outside Argentina [3,44–49].
Accordingly, although this clone is genetically related to the
international HA-MRSA ‘‘classical’’ Pediatric clone (ST5-SCCme-
cIV) identified in several countries [50], based on the molecular
characterization (CA-MRSA and CA-MSSA) and clinical epide-
miology over time, we suggest that this clone is a new epidemic
CA-MRSA, probably endowed with increased fitness in this
country. Hence, the possibility of being an escaped HA strain
should be ruled out.
Conversely, one of the three most predominant HA-MRSA
clones in Argentina since 1998 was clonally related to the Pediatric
clone by PFGE analysis [36,37] which was characterized as
ST100-SCCmecIV related to IVc-spa-t002-PVL
2 [15]. In Co ´rdo-
ba, some community-onset infections were caused by this HA-
MRSA clone before the emergence of the new CA-MRSA clone,
probably as an ‘‘escaped’’ HA-MRSA strain [12,15]. Accordingly,
it was more commonly isolated from HACO-MRSA cases than
from CA-MRSA infections (10% vs 2%), as shown herein. The
ST100 genotype was also identified in a MRSA isolate from
Zurich in 2003 (MRSA-ZH47), associated with the new
SCCmecIV(2B&5) [35]. In this study, we demonstrated for the
first time that the SCCmec associated with pulsotype C (Pediatric
clone)-ST100 in Argentina is closely related to SCCmecIV(2B&5).
Therefore, to classify this new variant of SCCmecIV, it would be
necessary to determine the complete nucleotide sequence, which is
currently in progress.
The pandemic Southwest Pacific-(SWP) clone or USA1100
was one of the minor clones found, accounting for 11.5% of CA-
MRSA isolates. It was characterized as pulsotype N, ST30, spa-
t019 and related ones. Most isolates harbored SCCmecIVc (97%)
all of them carried pvl genes and adhesins cna and bbp genes.
Since mid-1990s, this CA-MRSA clone, ST30-IV-PVL
+ with
different pulsotypes or spa types or SCCmecIV subtypes has been
reported from many regions of the world [1,46]. In Buenos
Aires, this clone (ST30-IV) had already been detected as a minor
one among CA-MRSA isolates in 2004–2006 [13]. In our study,
this clone was significantly more frequent in Buenos Aires city
and surrounding areas (21%) than in other regions analyzed,
where it accounted for 8% of CA-MRSA isolates in 2007.
Although its frequency is still very low, this situation might
suggest that this CA-MRSA clone is spreading from Uruguay,
where it is highly prevalent at community and hospital settings
[11,51].
Recently, the South American USA300 MRSA-(ST8-SSCme-
cIV-spat008-PVL
+-ACME
2) clone was described as the most
predominant (96%) CA-MRSA in northern areas of South
America between 2006 and 2008 [14]. An additional important
issue of this study was the finding of the first four cases of CA-
MRSA infections caused by this highly virulent CA-MRSA clone
in the southern cone of Latin America. ACME-negative variants
of USA300 also appear to be common in Western Australia and in
Spain [52–54], though we were unable to find eventual
epidemiological association between Argentinean strains and those
from these countries.
Our results confirmed the high prevalence of MRSA infections
in the community in Argentinean children, so the characteristics of
antimicrobial susceptibility of these strains must be considered for
the selection of empiric therapies. Although most CA-MRSA
isolates were susceptible to all non-b-lactam antibiotics, inducible
resistance to clindamycin (14%), resistance to gentamicin (8%),
rifampin (1%) and chloramphenicol (1%) were detected in isolates
belonging to ST5-IV-PVL
+ CA-MRSA clone (Table 3). It is
important to remark that this clone’s resistance to antibiotics was
only represented by clindamycin, just in 10% of isolates, as
described in the previous surveillance performed in Co ´rdoba
in2005 [12]. Hence, these results support the ability of the ST5-
IV-PVL
+ CA-MRSA clone to acquire new resistance determi-
nants. On the other hand, the higher rates of resistance to non-b-
lactam antibiotics detected among HACO-MRSA strains were
associated with traditional HA-MRSA clones in our country: the
Cordobes/Chilean, Brazilian and Pediatric clones. In addition,
according to these results, it would be possible to infer that the
presence of HRFs should be considered for selection of empirical
therapy in children with community-onset MRSA infections.
Importantly, in our study, three strains with h-VISA phenotype
from children with HRFs were detected. One of these cases and
another one detected in an adult patient without HRFs in 2009
[55] were PVL
2 variants of ST5-SCCmec-IV CA-MRSA clone.
Considering the high proportion of children with invasive CA-
MRSA infections caused by this clone, along with the fact that
vancomycin is still the centerpiece used for the treatment of this
type of CA-MRSA infections [7], this finding constitutes another
concern for public health.
Our study was limited by the use of the CDC criteria to identify
patients with infections caused by CA-MRSA isolates, which
appear to underestimate the burden of diseases produced by these
strains. Additionally, evidence from this study, though indirect,
indicate that CA-MRSA strains have entered the hospital settings
of Argentina and probably the burden of CA-MRSA is even
greater than shown here.
In conclusion, we observed a significant increase in the
incidence of invasive and non-invasive CA-MRSA infections, in
children of Co ´rdoba between 2005 and 2008. This raise could be
attributed entirely to the rapid dissemination of an epidemic CA-
MRSA clone characterized as I-ST5-SCCmecIVa-spa-t311-PVL
+.
Importantly, this highly virulent clone with capacity to express the
phenotype h-VISA, predominates in central, northern and eastern
regions of Argentina and still more worryingly, it has probably
entered the hospital settings. The specific virulence, antibiotic
resistance and transmission traits of a CA-MRSA clone distinct
from USA300 would need to be identified in order to recognize
priority targets for drug and vaccine development. These virulent
clones represent a new threat to public health in Argentina and
probably worldwide, warranting close monitoring during next
years.
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